Spontaneous immortalization of clinically normal colon-derived fibroblasts from a familial adenomatous polyposis patient

Neoplasia

Volumn 6, Issue 3, 2004, Pages 258-265

  Forsyth, Nicholas R ^a   Morales, Carmela P ^a,b   Damle, Shirish ^c   Boman, Bruce ^c   Wright, Woodring E ^c   Kopelovich, Levy ^d   Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Paul L Foster School of Medicine   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenomatous polyposis coli; Familial adenomatous polyposis; Spontaneous immortalization; Telomerase; Telomere

Indexed keywords

TELOMERASE;

ADENOMATOUS POLYP; ARTICLE; CANCER PREVENTION; CELL TYPE; CONTROLLED STUDY; DIPLOIDY; DNA DAMAGE; EXON; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; PRIORITY JOURNAL; SENESCENCE; TELOMERE; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

EID: 2442685324     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.4103     Document Type: Article

References (24)

1. Bisgaard ML, Fenger K, Bulow S, Niebuhr E, and Mohr J (1994). Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3, 121-125.
2. Fearnhead NS, Wilding JL, and Bodmer WF (2002). Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 64, 27-43.
3. Bodmer WF, Bailey CJ, Bodmer J, Bussey HJR, Ellis A, Gorman P, Lucibello FC, Murday VA, Rider SH, Scambler P, Sheer D, Solomon E, and Spurr NK (1987). Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328, 614-616.
4. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Lepaslier D, Abderrahim H, Cohen D, Leppert M, and White R (1991). Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589-600.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, and Bos JL (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525-532.
6. Beroud C and Soussi T (1996). APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 24, 121-124.
7. Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J, Frayling I, Efstathiou J, Pack K, Payne S, Roylance R, Gorman P, Sheer D, Neale K, Phillips R, Talbot I, Bodmer W, and Tomlinson I (1999). The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's "two-hit" hypothesis. Nat Med 5, 1071-1075.
8. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, and Polakis P (1998). Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8, 573-581.
9. Bright-Thomas RM and Hargest R (2003). APC, beta-catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer. Eur J Surg Oncol 29, 107-117.
10. Shay JW and Wright WE (2002). Telomerase: a target for cancer therapeutics. Cancer Cell 2, 257-265.
11. Tang R, Cheng AJ, Wang JY, and Wang TC (1998). Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res 58, 4052-4054.
12. Gollahon LS, Kraus E, Wu TA, Yim SO, Strong LC, Shay JW, and Tainsky MA (1998). Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts. Oncogene 17, 709-717.
13. Herbert BS, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, and Shay JW (2001). Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst 93, 39-45.
14. Kopelovich L (1993). Heritable colorectal cancer and cancer genes: systemic expressions. Mol Carcinog 8, 3-6.
15. Ramirez RD, Herbert BS, Vaughan MB, Zou Y, Gandia K, Morales CP, Wright WE, and Shay JW (2003). Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 22, 433-444.
16. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, and Shay JW (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
17. Ouellette MM, Liao M, Herbert BS, Johnson M, Holt SE, Liss HS, Shay JW, and Wright WE (2000). Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J Biol Chem 275, 10072-10076.
18. Forsyth NR, Evans AP, Shay JW, and Wright WE (2003). Developmental differences in the immortalization of lung fibroblasts by telomerase. Aging Cell 2, 235-243.
19. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, and Friend SH (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238.
20. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, and Ahnen DJ (2003). Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2, 885-892.
21. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, White MA, Wright WE, and Shay JW (1999). Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21, 115-118.
22. Shay JW, Van Der Haegen BA, Ying Y, and Wright WE (1993). The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 209, 45-52.
23. Ikeguchi M, Makino M, and Kaibara N (2000). Telomerase activity and p53 gene mutation in familial polyposis coli. Anticancer Res 20, 3833-3837.
24. Lin SY and Elledge SJ (2003). Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113, 881-889.